Bob Ingram is taking over as the chair of another corporate board. But don’t get the idea it’s an executive gravy train for the former GlaxoSmithKline exec-turned-venture capitalist and board member.

On Tuesday, RTP-based BioCryst Pharmaceuticals disclosed that Ingram had been named chair of its board at the company’s annual corporate meeting last week.

Ingram already:

  • Is lead director at LED and semiconductor giant Cree
  • Is chair at pharmaceutical firm Novan
  • ​Is a director at startup PhaseBio Pharmaceuticals
  • Is a member of the board at HBM Healthcare Investments, a Swiss firm
  • Is a board member at Malin Corporation, a life sciences firm in Ireland

Oh, not to be left off the list – Ingram also helps run Durham-based Hatteras Venture Partners where he has worked for a decade.

And don’t think for a moment Ingram has it easy in the corporate suites.

At Cree, Ingram must help find a replacement for soon-to-depart Chuck Swobodoa, the long-time serving chair and CEO.

And Novan has had its share of problems.

Not that Ingram isn’t used to corporate challenges.

As CEO and Chairman of GlaxoWellcome, he helped manage the merger with Glaxo that produced GSK.

At BioCryst, he succeeds George Abercrombie as chair. Ingram has been on the board since August 2015. Abercrombie had led BioCryst board over the past four years.

“During my time on the board, I have been impressed with BioCryst’s dedication to patients with rare disease and the pursuit of highly innovative therapies,” Ingram said in a statement.

“I am very excited to help guide BioCryst through what promises to be an exciting time as it initiates Phase 3 development and prepares for commercialization of BCX7353.”

In April, BioCryst (Nasdaq: BCRX) announced a new oral liquid formulation of BCX7353 for the treatment of acute attacks in patients with hereditary angioedema (HAE), a genetic condition that causes swelling of the skin.

“We are very fortunate to have Bob Ingram take the reins in leading our board as there are very few people with his long and successful record of leadership in the pharmaceutical industry, as well as his extensive experience on publicly-listed company boards,” noted BioCryst CEO Jon Stonehouse. “I look forward to working closely with him as we continue to build a successful rare disease company.”